Table 3.
Multivariate survival analysis of factors associated with progression to cervical SILs.
| Variables | Hazard ratio (95% Wald Robust CL) | P value |
|---|---|---|
| Antiretroviral therapy | 0.0004 | |
| HAARTa versus old HAARTb | 0.46 (0.31–0.69) | 0.0002 |
| HAART versus any ARTc | 0.35 (0.19–0.63) | 0.0005 |
| HAART versus no ART | 0.66 (0.47–0.918) | 0.0139 |
| HAART versus othersd | 0.47 (0.33–0.68) | <0.0001 |
| Increased CD4 counts (cells/mm3) | 0.0007 | |
| By 100 | 0.91 (0.86–0.96) | |
| By 200 | 0.82 (0.74–0.92) | |
| By 300 | 0.75 (0.63–0.89) | |
| By 500 | 0.62 (0.47–0.82) | |
| Duration of HIV infection (by 1 year) | 0.88 (0.85–0.91) | <0.0001 |
| Menopausal versus premenopausal (at mean age = 40.87) | 1.63 (1.03–2.58) | <0.0001 |
| Age and menopause interaction* | <0.0001 | |
| Meno yes versus no at age = 30 | 3.62 (1.83–7.17) | <0.0005 |
| Meno yes versus no at age = 40 | 1.74 (1.08–2.79) | <0.0050 |
| Meno yes versus no at age = 50 | 0.83 (0.57–1.22) | >0.5000 |
| Meno yes versus no at age = 60 | 0.40 (0.25–0.64) | <0.0005 |
| HIV infection from IV drug use (yes versus no) | 1.94 (1.33–2.84) | 0.0007 |
| Smoking status | 0.0306 | |
| Current smokers versus never smoked | 1.39 (0.99–1.95) | 0.0566 |
| Current smokers versus former smokers | 2.07 (1.04–4.16) | 0.0397 |
HAART: highly active antiretroviral therapy, ART: antiretroviral therapy.
aHAART: current standard HAART regimens (two or more nucleoside reverse transcriptase inhibitors (NRTIs) with a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitors (raltegravir) or salvage regimen.
bOld HAART: triple combination antiretroviral regimens containing indinavir, saquinavir, fosamprenavir, nelfinavir, or nevirapine.
cAny ART: not classified as HAART or old HAART.
dOthers: ART regimen except HAART (“old HAART” and “any ART”) and “no ART”.
*P values are approximations and ages are extrapolations from the regression equation.